Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qing Zou

Showing results (181-190 of 189) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 189 results.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|October 16, 2016
Differential miRNA expression in pleural effusions derived from extracellular vesicles of patients with lung cancer, pulmonary tuberculosis, or pneumoniaJin Lin, Yan Wang, Ye-Qing Zou, et al.
Journal of Clinical Laboratory Analysis|April 7, 2017
Differential expression of urinary exosomal microRNAs in IgA nephropathyQing-Hua Min, Xi-Min Chen, Ye-Qing Zou, et al.
Cancer Science|October 13, 2020
Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinomaDingwei Ye, Jiyan Liu, Aiping Zhou, et al.
Medicine|November 3, 2017
Identification of differential expressed PE exosomal miRNA in lung adenocarcinoma, tuberculosis, and other benign lesionsYan Wang, Yan-Mei Xu, Ye-Qing Zou, et al.
Signal Transduction and Targeted Therapy|December 17, 2024
Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 studyHongkai Wang, Shusuan Jiang, Hong Luo, et al.
The Lancet. Oncology|September 8, 2022
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trialWeijie Gu, Weiqing Han, Hong Luo, et al.
Asia-Pacific Journal of Clinical Oncology|October 14, 2020
Radium-223 in Asian patients with castration-resistant prostate cancer with symptomatic bone metastases: A single-arm phase 3 studyTie Zhou, Fangjian Zhou, Jianming Guo, et al.
Scientific Reports|February 3, 2016
The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinomaChao Qin, Qiang Cao, Pu Li, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2022
Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT)Xinan Sheng, Dingwei Ye, Aiping Zhou, et al.
Pageof 19

Showing results (181-190 of 189) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 189 results.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|October 16, 2016
Differential miRNA expression in pleural effusions derived from extracellular vesicles of patients with lung cancer, pulmonary tuberculosis, or pneumoniaJin Lin, Yan Wang, Ye-Qing Zou, et al.
Journal of Clinical Laboratory Analysis|April 7, 2017
Differential expression of urinary exosomal microRNAs in IgA nephropathyQing-Hua Min, Xi-Min Chen, Ye-Qing Zou, et al.
Cancer Science|October 13, 2020
Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinomaDingwei Ye, Jiyan Liu, Aiping Zhou, et al.
Medicine|November 3, 2017
Identification of differential expressed PE exosomal miRNA in lung adenocarcinoma, tuberculosis, and other benign lesionsYan Wang, Yan-Mei Xu, Ye-Qing Zou, et al.
Signal Transduction and Targeted Therapy|December 17, 2024
Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 studyHongkai Wang, Shusuan Jiang, Hong Luo, et al.
The Lancet. Oncology|September 8, 2022
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trialWeijie Gu, Weiqing Han, Hong Luo, et al.
Asia-Pacific Journal of Clinical Oncology|October 14, 2020
Radium-223 in Asian patients with castration-resistant prostate cancer with symptomatic bone metastases: A single-arm phase 3 studyTie Zhou, Fangjian Zhou, Jianming Guo, et al.
Scientific Reports|February 3, 2016
The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinomaChao Qin, Qiang Cao, Pu Li, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2022
Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT)Xinan Sheng, Dingwei Ye, Aiping Zhou, et al.
Pageof 19